Next Article in Journal
Sumac Silver Novel Biodegradable Nano Composite for Bio-Medical Application: Antibacterial Activity
Next Article in Special Issue
Duchenne Muscular Dystrophy: From Diagnosis to Therapy
Previous Article in Journal
68Ga-Based Radiopharmaceuticals: Production and Application Relationship
Previous Article in Special Issue
Comparative Label-Free Mass Spectrometric Analysis of Mildly versus Severely Affected mdx Mouse Skeletal Muscles Identifies Annexin, Lamin, and Vimentin as Universal Dystrophic Markers

Molecules 2015, 20(7), 12944-12945; https://doi.org/10.3390/molecules200712944

Editorial
Special Issue—Towards Understanding the Mechanisms and Curing of Muscular Dystrophy Diseases
The Cyprus Institute of Neurology & Genetics, PO Box 23462, 1683 Nicosia, Cyprus
Academic Editor: Derek J. McPhee
Received: 14 July 2015 / Accepted: 16 July 2015 / Published: 16 July 2015

Muscular dystrophies are a heterogeneous group of inherited diseases with different molecular basss, but sharing similar clinical features and dystrophic changes. Understanding disease mechanisms for muscular dystrophies and, moreover, finding efficient and permanent ways of curing them remains challenging. The purpose of this issue was to include manuscripts which aim at addressing the understanding of disease mechanisms in muscular dystrophies and ways to tackle them. Two reviews and three original articles compose the current Special Issue [1,2,3,4,5]. Two of the articles describe new methods for the identification of biomarkers in Duchenne Muscular Dystrophy [1,2]; a non-invasive method in the sera of patients [1] and a muscle-specific approach in the known mdx animal model [2]. Moreover, a paper in this Special Issue describes how cell culture conditions affect gene expression in Facioscapulohumeral muscular dystrophy myoblasts [3]. Finally, three reviews describe, in a very comprehensive way, ways to tackle muscular dystrophy through model organisms [4], and the current understanding of the pathology and treatment of cardiomyopathy in Duchenne Muscular Dystrophy [5,6].

References

  1. Anaya-Segura, M.A.; García-Martínez, F.A.; Montes-Almanza, L.Á.; Díaz, B.-G.; Ávila-Ramírez, G.; Alvarez-Maya, I.; Coral-Vázquez, R.M.; Mondragón-Terán, P.; Escobar-Cedillo, R.E.; García-Calderón, N.; et al. Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection. Molecules 2015, 20, 11154–11172. [Google Scholar] [CrossRef] [PubMed]
  2. Holland, A.; Henry, M.; Meleady, P.; Winkler, C.K.; Krautwald, M.; Brinkmeier, H.; Ohlendieck, K. Comparative Label-Free Mass Spectrometric Analysis of Mildly versus Severely Affected mdx Mouse Skeletal Muscles Identifies Annexin, Lamin, and Vimentin as Universal Dystrophic Markers. Molecules 2015, 20, 11317–11344. [Google Scholar] [CrossRef] [PubMed]
  3. Pandey, S.N.; Khawaja, H.; Chen, Y.-W. Culture Conditions Affect Expression of DUX4 in FSHD Myoblasts. Molecules 2015, 20, 8304–8315. [Google Scholar] [CrossRef] [PubMed]
  4. Plantié, E.; Migocka-Patrzałek, M.; Daczewska, M.; Jagla, K. Model Organisms in the Fight against Muscular Dystrophy: Lessons from Drosophila and Zebrafish. Molecules 2015, 20, 6237–6253. [Google Scholar] [CrossRef] [PubMed]
  5. van Westering, T.L.E.; Betts, C.A.; Wood, M.J.A. Current Understanding of Molecular Pathology and Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy. Molecules 2015, 20, 8823–8855. [Google Scholar] [CrossRef] [PubMed]
  6. Nakamura, A. X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy. Pharmaceuticals 2015, 8, 303–320. [Google Scholar] [CrossRef] [PubMed]
Back to TopTop